No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
BBIO250117C15000
- 11.90
- -2.10-15.00%
15min DelayTrading Dec 23 09:30 ET
11.90High11.90Low
11.90Open14.00Pre Close1 Volume440 Open Interest15.00Strike Price1.19KTurnover170.70%IV-2.50%PremiumJan 17, 2025Expiry Date12.59Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9451Delta0.0090Gamma2.11Leverage Ratio-0.0288Theta0.0090Rho2.00Eff Leverage0.0080Vega
Intraday
- 5D
- Daily
News
BridgeBio Pharma Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $50
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Optimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic Initiatives
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49
BridgeBio Pharma Analyst Ratings